| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Biapenem (also called L-627, CLI 86815, LJC10627) is a potent carbapenem antibiotic with activity against both Gram-positive and Gram-negative bacterial strains. Biapenem has activity comparable to those of Imipenem and Meropenem against all groups of anaerobes with MICs for 90% of the strains tested of 0.06 to 2 mg/mL. Biapenem is more active than ampicillin-sulbactam, ticarcillin-clavulanate, piperacillin, cefoxitin, cefotaxime, and ceftriaxone. Biapenem is also active against all of the B. capillosus, Prevotella, Clostridium, and Eubacterium strains and anaerobic cocci tested. Biapenem shows broad antibacterial activity against both Gram-positive and Gram-negative clinical isolates.
| Targets |
β-lactam
|
||
|---|---|---|---|
| ln Vitro |
Biapenem has activity comparable to those of Imipenem and Meropenem against all groups of anaerobes with MICs for 90% of the strains tested of 0.06 to 2 mg/mL. Biapenem is more active than ampicillin-sulbactam, ticarcillin-clavulanate, piperacillin, cefoxitin, cefotaxime, and ceftriaxone. Biapenem is also active against all of the B. capillosus, Prevotella, Clostridium, and Eubacterium strains and anaerobic cocci tested. Biapenem shows broad antibacterial activity against both Gram-positive and Gram-negative clinical isolates. Biapenem is found to be approximately as active as imipenem, inhibiting 90% of isolates of most species at concentrations within one dilution of the MIC of imipenem for 90% of the isolates.
|
||
| ln Vivo |
|
||
| Animal Protocol |
|
||
| References | |||
| Additional Infomation |
Biapenem is a carbapenem antibiotic in which the azetidine and pyrroline rings carry 1-hydroxymethyl and pyrazolo[1,2-a][1,2,4]triazolium-6-ylthio substituents respectively. It has a role as an antibacterial drug. It is a member of carbapenems, a pyrazolotriazole and an organic sulfide.
Biapenem has been used in trials studying the treatment of Bacterial Infections. Biapenem is a 1-beta-methylcarbapenem antibiotic with a wide range of antibacterial activity. Biapenem has similar antibacterial activity to that of imipenem, but is more stable against human renal dehydropeptidase-I and with less neurotoxicity. |
| Molecular Formula |
C15H18N4O4S
|
|
|---|---|---|
| Molecular Weight |
350.39
|
|
| Exact Mass |
350.104
|
|
| Elemental Analysis |
C, 51.42; H, 5.18; N, 15.99; O, 18.26; S, 9.15
|
|
| CAS # |
120410-24-4
|
|
| Related CAS # |
|
|
| PubChem CID |
71339
|
|
| Appearance |
White to off-white solid powder
|
|
| Melting Point |
265-271°C (dec.)
|
|
| Index of Refraction |
1.651
|
|
| LogP |
1.4
|
|
| Hydrogen Bond Donor Count |
1
|
|
| Hydrogen Bond Acceptor Count |
6
|
|
| Rotatable Bond Count |
3
|
|
| Heavy Atom Count |
24
|
|
| Complexity |
609
|
|
| Defined Atom Stereocenter Count |
4
|
|
| SMILES |
S(C1([H])C([H])([H])N2C([H])=NC([H])=[N+]2C1([H])[H])C1=C(C(=O)[O-])N2C([C@]([H])([C@@]([H])(C([H])([H])[H])O[H])[C@@]2([H])[C@@]1([H])C([H])([H])[H])=O
|
|
| InChi Key |
MRMBZHPJVKCOMA-WAOAVRLKSA-N
|
|
| InChi Code |
InChI=1S/C15H18N4O4S/c1-7-11-10(8(2)20)14(21)19(11)12(15(22)23)13(7)24-9-3-17-5-16-6-18(17)4-9/h5-11,20H,3-4H2,1-2H3/t7-,8?,10-,11-/m1/s1
|
|
| Chemical Name |
(4R,5S,6S)-3-((6,7-dihydro-5H-pyrazolo[1,2-a][1,2,4]triazol-4-ium-6-yl)thio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
|
|
| Synonyms |
Biapenem; CL 186,815; CL-186,815; CL186,815; L 627; L-627; L627; LJC 10,627; LJC-10,627; LJC10,627; RPX2003; RPX 2003; RPX-2003; Omegacin;
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Water : 5~10 mg/mL(~28.54 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 11.11 mg/mL (31.71 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication (<60°C).
Solubility in Formulation 2: PBS: 11.11 mg/mL (31.71 mM) (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8540 mL | 14.2698 mL | 28.5396 mL | |
| 5 mM | 0.5708 mL | 2.8540 mL | 5.7079 mL | |
| 10 mM | 0.2854 mL | 1.4270 mL | 2.8540 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA